Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 347

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 347
---
,030 | ) |
| Basic and diluted loss per share (in USD)                                                    |     | $                                             |      (0.08 | ) |     | $                |       (0.32 | ) |     |             |       — |     |       |     |             |        — |     |       |     | $         |       (0.58 | ) |
| Weighted average common shares used in computing basic and diluted net loss per common share |     |                                               |  4,193,689 |   |     |                  |     954,401 | * |     |             |         |     |       |     |             |          |     |       |     |           |  26,746,852 |   |

____________ *This gives effect to the reverse stock split of 1 -for-40as of September 27, 2024. The accompanying notes are an integral part of these unaudited pro forma condensed combined financial statements.

194 Kadimastem Ltd. & NLS Pharmaceutics Ltd.
Notes to accompanying Financial Statements 1. Description of the Proposed Transaction and Basis of Presentation NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (“NLS”), a biopharmaceutical company, and Kadimastem Ltd. (TASE: KDST.TA”) (“Kadimastem”), a clinical -stagecell therapy company developing and manufacturing “off -the-shelf” allogeneic cell products for the treatment of neurodegenerative diseases and potential cure of diabetes, announced on November 4, 2024 that they have entered into a definitive merger agreement (the “Merger Agreement”) to combine the two companies to focus on advancing NLS’s promising, first -inclass Dual Orexin Agonist platform (“DOXA”) and Kadimastem’s allogenic cell therapy program with its clinical assets (mainly targeting diabetes and amyotrophic lateral sclerosis (ALS), with Phase 2a studies that are planned to be initiated in the U.S. following the closing of the transaction). AstroRx ®Phase 2a study cost estimation is about $12million. The necessary steps for study initiation include completion of AstroRx ®clinical production by contract development and manufacturing organization and contract signing with medical centers and clinical teams. Following the closing of the transactions contemplated by the Merger Agreement (the “Closing”), NLS intends to divest its other legacy assets (including the mazindol ER but excluding the